Read More Pharma Industry News Deep Apple Therapeutics signs $812m global deal with Novo Nordisk for oral cardiometabolic drugs Deep Apple inks up to $812M deal with Novo Nordisk to advance oral GPCR drugs for obesity and metabolic diseases. Explore the science behind the strategy. byPallavi MadhirajuJune 11, 2025